Premium
Expression of proton‐sensing G‐protein‐coupled receptors in selected skin tumors
Author(s) -
Nassios Anaïs,
Wallner Susanne,
Haferkamp Sebastian,
Klingelhöffer Christoph,
Brochhausen Christoph,
Schreml Stephan
Publication year - 2019
Publication title -
experimental dermatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.108
H-Index - 96
eISSN - 1600-0625
pISSN - 0906-6705
DOI - 10.1111/exd.13809
Subject(s) - receptor , g protein coupled receptor , protein expression , g protein , chemistry , microbiology and biotechnology , biology , computational biology , cancer research , biochemistry , gene
Background In humans, there are four known proton‐sensing G‐Protein‐coupled receptors (pH‐GPCRs): GPR4 (GPR19), TDAG8 (GPR65, T‐cell death‐associated gene 8), OGR1 (GPR68, ovarian cancer GPCR1) and G2A (GPR132, G2 accumulation protein). They are known to be involved in sensing changes of extracellular proton concentrations in the acidic microenvironment of tumors, which leads to altered cell proliferation, migration, metastasis, immune cell function and inflammation. However, little is known about the expression of pH‐GPCRs in the skin and especially skin cancers. Aim We studied the expression of pH‐GPCRs in selected skin cancers, that is Merkel cell carcinoma ( MCC ), dermatofibrosarcoma protuberans ( DFSP ), atypical fibroxanthoma ( AFX ) and pleomorphic dermal sarcoma ( PDS ). Methods We did immunohistochemistry and immunofluorescence to analyse the expression of GPR4, TDAG8, OGR1 and G2A using paraffin‐embedded tissue samples (n = 4, exceptions: PDS GPR4/GPR65 n = 5, AFX GPR132 n = 3) from patients suffering from MCC , DFSP , AFX and PDS . Results (a) GPR4 was expressed on all AFX and PDS specimens. All AFX and MCC showed a positive expression of G2A. All PDS exhibited a strong positive expression of G2A. (b) MCC s neither expressed GPR4 nor TDAG8. All DFSP showed no expression of TDAG8. (c) For any other combination of GPCR and skin disease, we found positive/negative mixed results. Conclusions These are the first results on pH‐GPCRs in selected skin cancers. We provide evidence that these GPCRs are differentially expressed on the various types of skin cancers and that they can potentially be addressed as a therapeutic target in extensive disease.